ArticleApplied biochemistry and biotechnology2026
RBM15 Contributes to Bladder Carcinoma Progression via m6A-dependent Stabilization of IFI6 mRNA.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder carcinoma (BLCA) is a prevalent urological malignancy with limited therapeutic options. Interferon α inducible protein 6 (IFI6) is implicated in various cancers, but its role in BLCA remains unexplored. qRT-PCR and western blot were used for expression analysis. Functional assays (cell counting kit 8, 5-ethynyl-2'-deoxyuridine staining, flow cytometry, wound healing, transwell, and 2', 7'-dichlorodihydrofluorescein diacetate fluorescent probe) and xenograft mouse models were used to assess the effects of IFI6 and RNA binding motif protein 15 (RBM15) on BLCA. The N6-methyladenosine (m6A) modification sites on IFI6 were predicted by the sequence-based RNA adenosine methylation site predictor website and the combination of RBM15 was validated via RNA-binding proteins site prediction websites, methylated RNA immunoprecipitation, Actinomycin D, dual-luciferase reporter assay, and RNA binding protein immunoprecipitation assays. IFI6 was elevated in BLCA tissues and cells. IFI6 knockdown could inhibit proliferation, migration, and invasion, while enhancing apoptosis and oxidative stress of BLCA cells. Besides, silencing of IFI6 blocked BLCA tumor growth. RBM15, an m6A writer, directly bound IFI6 to stabilize its mRNA through m6A modification. Rescue experiments confirmed that IFI6 overexpression reversed RBM15 knockdown-mediated the suppression effect on BLCA cell proliferation and metastasis. Our study identifies that RBM15/IFI6 axis is a novel m6A-dependent pathway driving BLCA progression, offering a potential therapeutic target for BLCA.
Indexed as
Identifiers
42753073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.